Phio Pharmaceuticals Corp. (NASDAQ:PHIO) Sees Significant Decline in Short Interest

Phio Pharmaceuticals Corp. (NASDAQ:PHIOGet Free Report) was the recipient of a large drop in short interest in June. As of June 15th, there was short interest totalling 152,000 shares, a drop of 14.2% from the May 31st total of 177,100 shares. Based on an average trading volume of 207,800 shares, the days-to-cover ratio is presently 0.7 days. Currently, 3.3% of the company’s stock are short sold.

Phio Pharmaceuticals Stock Performance

NASDAQ PHIO opened at $0.69 on Friday. The firm has a market cap of $3.18 million, a PE ratio of -0.21 and a beta of 1.40. Phio Pharmaceuticals has a one year low of $0.50 and a one year high of $3.23. The firm’s fifty day moving average is $0.74 and its two-hundred day moving average is $0.74.

Phio Pharmaceuticals (NASDAQ:PHIOGet Free Report) last posted its quarterly earnings data on Thursday, May 9th. The company reported ($0.47) EPS for the quarter. Research analysts predict that Phio Pharmaceuticals will post -1.82 earnings per share for the current year.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “buy” rating and set a $4.00 price target on shares of Phio Pharmaceuticals in a research note on Tuesday, May 14th.

Get Our Latest Stock Report on Phio Pharmaceuticals

Phio Pharmaceuticals Company Profile

(Get Free Report)

Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. The company develops PH-762, INTASYL compound which reduces the expression of cell death Protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; PH-894 that silences the BRD4, a protein which controls gene expression in both T cells and tumor cells, effecting the immune system as well as the tumor; and PH-804 that targets the TIGIT, a protein which inhibits the activity of Natural Killer cells.

Featured Stories

Receive News & Ratings for Phio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phio Pharmaceuticals and related companies with's FREE daily email newsletter.